Bristol Myers Squibb Company (NYSE:BMY) Receives $56.86 Average Price Target from Analysts

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been given an average rating of “Hold” by the twenty-one ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $56.8571.

BMY has been the topic of a number of research reports. HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Wells Fargo & Company increased their target price on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Morgan Stanley reissued an “underweight” rating and set a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price objective for the company from $52.00 to $61.00 in a research note on Monday, December 15th.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently made changes to their positions in the stock. Florida Trust Wealth Management Co increased its holdings in shares of Bristol Myers Squibb by 4.5% in the 4th quarter. Florida Trust Wealth Management Co now owns 39,137 shares of the biopharmaceutical company’s stock valued at $2,111,000 after acquiring an additional 1,700 shares during the last quarter. Signaturefd LLC boosted its holdings in Bristol Myers Squibb by 0.9% in the fourth quarter. Signaturefd LLC now owns 95,847 shares of the biopharmaceutical company’s stock valued at $5,170,000 after purchasing an additional 857 shares in the last quarter. Advocate Group LLC increased its stake in Bristol Myers Squibb by 5.8% in the fourth quarter. Advocate Group LLC now owns 165,670 shares of the biopharmaceutical company’s stock valued at $8,936,000 after purchasing an additional 9,076 shares during the last quarter. Princeton Global Asset Management LLC raised its holdings in Bristol Myers Squibb by 82.5% during the fourth quarter. Princeton Global Asset Management LLC now owns 3,364 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Ascent Group LLC lifted its position in shares of Bristol Myers Squibb by 31.4% during the 4th quarter. Ascent Group LLC now owns 20,575 shares of the biopharmaceutical company’s stock worth $1,110,000 after buying an additional 4,919 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $54.20 on Friday. The company has a market capitalization of $110.34 billion, a P/E ratio of 18.31, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $63.33. The stock’s fifty day moving average is $52.18 and its two-hundred day moving average is $48.24.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 85.14%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY signed a collaboration with Microsoft to use its AI-enabled radiology platform to speed early detection of lung cancer — a strategic move that could strengthen diagnostics, clinical trial readouts and long-term oncology positioning. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: Scotiabank highlighted BMY as an appealing 2026 investment and raised its price target (reported lift to $60 from $53), which could support investor sentiment if other analysts follow. Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026
• Positive Sentiment: BMS extended a deal with Syngene, keeping manufacturing and R&D continuity intact — a modest operational positive for supply chain stability. BMS extends deal with Syngene
• Neutral Sentiment: A Zacks comparison piece contrasts BMY with GSK on portfolio and prospects; useful for longer-term allocation decisions but not an immediate catalyst. BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
• Neutral Sentiment: Coverage in ETF/blue‑chip lists and investor videos (dividend ETF roundups, “top blue‑chip” buys) reinforces BMY’s image as a reliable large-cap dividend/defensive healthcare name but is more background than a fresh catalyst. 3 Dividend Income ETFs That Offer High Yields And Growth 2 Top Blue-Chip Stocks to Buy and Hold in 2026
• Neutral Sentiment: Mentions in broader investor roundups (e.g., MarketBeat on Buffett-related names) keep BMY in view for income/ value investors but don’t constitute direct drivers. 2 Buffett Stocks to Load Up On—And 1 to Ditch (BMY)

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.